HER2+ Early Breast Cancer: Who Can Safely Receive Less?
Generated October 2026 · Clinical Deep Dive0 CommentsTreatment for early HER2-positive breast cancer is moving in two directions. For some patients, the question is how much therapy can safely be stripped...
Generated October 2026 · Clinical Deep Dive 0 Comments Treatment for early HER2-positive breast cancer is moving in two directions. For some patients, the question is how much therapy can safely be stripped away — and the data increasingly support doing so. At the other end of the risk spectrum, new data are supporting treatment escalation for patients with high-risk disease or residual invasive disease after neoadjuvant therapy.
“Some patients can safely receive less intensive therapy, while others need escalation,” says Yara Abdou, MD, associate professor in the Division of Oncology at the University of North Carolina School of Medicine and UNC Lineberger Comprehensive Cancer Center ( Medscape ). The Floor has Dropped; the Ceiling Just Rose In May 2026, the FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) as neoadjuvant therapy followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer and as adjuvant therapy for patients with residual invasive disease after surgery ( FDA Prescribing Information ).
On September 17, 2026, the EMA's human medicines committee (CHMP) recommended T-DXd only for the post-neoadjuvant (residual disease) indication in the EU — narrower than the FDA's dual neoadjuvant-and-adjuvant approval — with a European Commission decision still pending ( EMA ). Meanwhile, contemporary neoadjuvant trials report 3-year event-free survival above 90% — even with shortened chemotherapy, or none at all, in carefully selected responders ( Lancet ; Lancet Oncology ).
The challenge is knowing which patients belong in which group. Where the Evidence for De-escalation Stands Not all de-escalation is created equal. The evidence ranges from randomized phase 3 data to promising single-arm phase 2 studies.
Here's the hierarchy: Well-established: Anthracycline omission with dual HER2 blockade. TRAIN-2 showed no pathologic complete response (pCR) difference between anthracycline-containing and anthracycline-free regimens (67% vs. 68%), with far less febrile neutropenia in the anthracycline-free arm.
Cardiac toxicity was rare in both regimens. ( Lancet Oncology ). Supported in selected patients: Carboplatin omission has phase 3 noninferiority evidence from neoCARHP, while MRI-guided shortening of chemotherapy has promising phase 2 data from TRAIN-3. The evidence is encouraging but more limited than for anthracycline omission. ( JCO ; Lancet Oncology ).
Trial-only: Chemotherapy-free, PET- or pCR-adapted strategies (PHERGain, PHERGain-2). Promising. Not ready for routine practice ( Lancet ; Annals of Oncology ).
Stage I: Paclitaxel-trastuzumab Remains the Standard Twelve weeks of paclitaxel plus a year of trastuzumab produced 10-year breast cancer-specific survival of 98.8% in the APT trial — establishing a de-escalated standard for appropriately selected patients. ( Lancet Oncology ; Annals of Oncology ).
Trastuzumab emtansine (T-DM1) offers another option, but the ATEMPT data have not established it as superior to paclitaxel-trastuzumab. ATEMPT's 5-year data showed 97.0% invasive disease-free survival (IDFS) with T-DM1 — comparable efficacy, different toxicity profile (less neuropathy and alopecia, more thrombocytopenia and early discontinuation) ( JCO ).
The genuinely contested zone is T1c tumors near 2 cm. St Gallen 2025 treats paclitaxel-trastuzumab as a standard option here. But in an exploratory KATHERINE analysis of 76 patients with cT1cN0 tumors, no invasive-disease events or deaths occurred among the 44 patients assigned to T-DM1 versus 8 of 32 on trastuzumab alone — The caveat here is, while numbers are striking, the subgroup was small and not powered to establish a treatment difference. ( NEJM ).
Stage II–III: Trimming the Backbone, Carefully Carboplatin omission is gaining traction. neoCARHP, a phase 3 non-inferiority trial out of China, found pCR of 64.1% with taxane-trastuzumab-pertuzumab (THP) alone versus 65.9% with added carboplatin (TCbHP) — non-inferiority met, with roughly half the rate of grade 3–4 adverse events ( JCO ).
“In all, carboplatin adds very little, if anything,” says Kathy Miller, MD, co-leader of the breast cancer program at Indiana University Health ( Medscape ). But the stage III subgroup in neoCARHP was underpowered, and St Gallen still favors TCbHP for stage III and inflammatory disease specifically because long-term recurrence data for the carboplatin-free regimen don't yet exist there ( Annals of Oncology ).
Continue reading
Watch a short ad to unlock the full article
The rest stays locked if you skip or close the ad early.
MRI-guided early surgery (TRAIN-3) allowed selected responders to proceed to surgery after as few as 1–3 cycles, with 3-year event-free survival above 96% in that group. The catch: MRI predicted pCR in 87% of hormone receptor-negative responders but only 53% of hormone receptor-positive ones.
Translation — this strategy works best in HR-negative disease and needs real caution in HR-positive disease ( Lancet Oncology ). A Genuinely Radical Idea: No Chemotherapy at all This is where the field splits hardest. PHERGain used early PET response to identify patients who could skip chemotherapy entirely on trastuzumab-pertuzumab alone.
Among PET responders who achieved pCR and received no chemotherapy, 3-year invasive disease-free survival was 96.4%, with no distant recurrences ( Lancet ). PHERGain-2 pushed further, dropping PET and relying on pCR alone in a highly selected population with IHC 3+, node-negative tumors no larger than 3 cm: 99.5% of patients avoided chemotherapy altogether ( Annals of Oncology ).
The options camps: Why the results are encouraging: Short-term outcomes in responders are excellent across three independent European programs (PHERGain, PHERGain-2, West German Study Group (WSG) pooled analysis) ( Lancet ; Annals of Oncology ). Why they aren’t yet practice-changing: None of these trials is powered for survival or randomized against standard chemotherapy.
St Gallen 2025 is blunt about it: anti-HER2 therapy with chemotherapy “remains the mainstay” of treatment ( Annals of Oncology ). Seven of approximately 86 patients in PHERGain's chemo-free arm progressed before surgery — a signal that upfront selection still isn't perfect ( The Lancet ).
Bottom line: These chemotherapy-free strategies remain investigational and should not yet be considered routine care outside clinical trials or highly specialized settings. Trastuzumab Duration: 6 months Is Real, 9 Weeks Is Not A 2025 individual-patient-data meta-analysis pooling five trials (11,389 patients) found 6 months of trastuzumab is non-inferior to 12 months for invasive disease-free survival, distant relapse-free survival, and overall survival — in low-risk patients on single-agent trastuzumab ( BMJ Oncology ).
Nine weeks failed non-inferiority outright. The authors are explicit that these conclusions don't extend to patients now getting dual HER2 blockade or post-neoadjuvant T-DM1 ( BMJ Oncology ). Where De-escalation Becomes Standard Stops Cold Residual invasive disease after neoadjuvant therapy remains the clearest signal that a patient needs more, not less.
KATHERINE's final survival analysis showed T-DM1 cut the risk of invasive disease events by nearly half versus trastuzumab alone (7-year IDFS 80.8% vs. 67.1%) ( NEJM ). Now DESTINY-Breast05 has positioned T-DXd to replace T-DM1 as the standard treatment for high-risk residual disease, with a 3-year IDFS of 92.4% versus 83.7% for T-DM1 ( NEJM ).
This is where the controversial part comes in: both the FDA label and the pending EU indication are written more broadly than the trial that supports them. DESTINY-Breast05 enrolled only high-risk residual disease — inoperable at presentation, or node-positive after neoadjuvant therapy.
The FDA label covers any residual invasive disease ( FDA Prescribing Information ). NCCN has already moved to restrict T-DXd to the DESTINY-Breast05 high-risk definition specifically because of this gap ( NCCN ). Questions also remain about how much weight to give pCR gains when long-term outcome data are immature.
A critique in European Journal of Cancer notes that the 11.2-percentage-point pCR gain in DESTINY-Breast11 fell short of the trial's own 15-point design target and below the surrogate threshold effect the authors estimate would be needed to predict an iDFS benefit ( European Journal of Cancer ).
And T-DXd isn't free. Adjudicated interstitial lung disease occurred in 9.6% of patients on T-DXd in DESTINY-Breast05 versus 1.6% on T-DM1, including two deaths ( NEJM ). “Coordination with pulmonology and radiology is especially important because distinguishing T-DXd pneumonitis from radiation pneumonitis can be clinically challenging,” Abdou notes ( Medscape ).
Inflammatory Breast Cancer: Don't Extrapolate The de-escalation strategy discussed here do not apply to inflammatory breast cancer. St Gallen 2025 calls for axillary dissection and postmastectomy radiotherapy regardless of response, and favors carboplatin-containing regimens ( Annals of Oncology ).
Wendy Woodward, MD, PhD, executive director of the inflammatory breast cancer (IBC) clinic at MD Anderson Cancer Center, warns that this distinction is getting lost in practice: “Most people have very little experience diagnosing or treating IBC and fall into more familiar norms that are trending toward de-escalation” ( Medscape ).
What Your Peers Are Saying “The times may be ripe to omit carboplatin for the neoadjuvant treatment of HER2+ breast cancer,” wrote Paolo Tarantino, MD, PhD, of the breast oncology program at Dana-Farber Brigham Cancer Center, in a Journal of Clinical Oncology editorial on the neoCARHP trial ( Medscape ) On why MRI-guided chemotherapy shortening is harder to trust in hormone receptor-positive disease: “HR-positive disease appears more diffuse and less well defined on MRI, making it harder to determine whether tumors are truly gone,” Gabe S.
Sonke, MD, PhD, Department of Medical Oncology at the Netherlands Cancer Institute and a TRAIN-3 investigator, told Medscape Medical News ( Medscape ) “People are hopeful that ctDNA tests become standards of care, but they're by no means standards of care in 2026,” said Mark G. Kris, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center — a caution that applies directly to HER2-positive disease, where no trial has yet shown that acting on a ctDNA result changes outcomes ( Medscape ) The Bottom Line The evidence now supports a more individualized approach to early HER2-positive breast cancer — but not every promising de-escalation strategy is ready for routine care, and not every high-risk patient belongs on the same escalation pathway.
The key is to match the intensity of treatment to the population in which that strategy has actually been studied. For selected patients, that may mean safely omitting components of chemotherapy or shortening treatment. For patients with residual or otherwise high-risk disease, the evidence increasingly supports escalation.
And where the evidence remains immature — particularly chemotherapy-free strategies — clinical trials should remain the path forward. Medscape Medical News © 2026 WebMD, LLC Send comments and news tips to news@medscape.net . Cite this: HER2-Positive Breast Cancer in 2026: The Treatment Map Is Getting More Complicated - Medscape - October 09, 2026.
Article text via FreeNewsAPI. Rights remain with Medscape.
Read on publisher site → Opens Medscape in a new tab
